Healthcare resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): results from PREAMBLE

6621Background: PREAMBLE (Prospective REsearch Assessment in multiple Myeloma: an oBservationaL Evaluation; NCT01838512) is an observational cohort study on the real-world effectiveness of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and combination therapy for RRMM. We report preliminary data on HCRU on the overall study population (US and Europe). Methods: Eligibility criteria: patients (pts) aged ≥ 18 y with RRMM ( ≥ 1 prior therapy) who initiated treatment with an IMiD, PI, or IMiD+PI 90 days prior/30 days after study enrollment. Pt data collected at each healthcare provider (HCP) visit included number of clinic/physician office visits, home healthcare, hospital outpatient and emergency room visits, and hospitalizations. Results: At data cut-off (Dec 2015), 764 treated pts (median age 68 y, 55% male) were enrolled; 599 (78%) relapsed, 161 (21%) refractory. Median time from diagnosis to index MM therapy was 41 mo (range 24–71). Of the 764 pts, 365 (48%) had prior transplantation experie...